CG Oncology CEO Arthur Kuan Buys $2.37M of Stock in Open Market
CGON has more than doubled off its 52-week low of $37.01.
Summary
CG Oncology's CEO Arthur Kuan bought 30,000 shares at $78.88 for about $2.37 million on 2026-11-18, his own money two days after positive PIVOT-006 Phase 3 data and a reversal from this summer's insider selling.
Key Events · Ownership and Investor Activity · CGON
-
CEO Open-Market Purchase
Chief Executive Officer and director Arthur Kuan acquired 30,000 shares at $78.88 on 2026-11-18, a total of $2,366,425.24, held directly.
-
Holdings After the Buy
Post-transaction direct ownership stands at 228,916 shares.
-
Timed to PIVOT-006 Data
The purchase comes two days after the 2026-11-16 disclosure that Phase 3 PIVOT-006 met its primary endpoint, cutting recurrence risk 68% versus surveillance.
-
Reverses Summer Selling Pattern
The buy contrasts with repeated Form 144 filings by former President and COO Ambaw Bellete from August through September 2026.
Analysis · CGON · Life Sciences
The CEO put $2.37 million of his own money into the stock at $78.88, two days after the PIVOT-006 Phase 3 win cut recurrence risk 68%. That is real cash, not an option exercise, and it is roughly eight times the size of the CCO's purchase reported the same day. The dollar amount is modest next to a multi-billion-dollar market value, so read it as a confidence gesture rather than a thesis-changing bet — but it lands against a summer of steady insider selling (former COO Ambaw Bellete filed repeatedly from August into September), which makes the direction change the notable part.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGON was trading at $79.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $37.01 to $93.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.